Catalent Pharma Solutions, Inc. Credit Rating

Resultados 1 - 50 de 76

Página de 2 Next

Filtrar por:

Fecha	Tipo de Informe	Título	Fuente
13 Feb 2024	Credit Opinion	Catalent Pharma Solutions, Inc.: Ratings on review for upgrade pending acquisition by Novo Holdings	Moody's Investors Service
06 Feb 2024	Rating Action	Moody's places Catalent's ratings under review for upgrade on proposed acquisition by Novo Holdings	Moody's Investors Service
11 Dec 2023	Rating Action	Moody's assigns Ba2 rating to Catalent's new incremental first lien term loan	Moody's Investors Service
25 Sep 2023	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Business and Consumer Service issuers	Moody's Investors Service
05 Jul 2023	Credit Opinion	Catalent Pharma Solutions, Inc.: High leverage to gradually improve as revenue growth and cost initiatives drive earnings' recovery	Moody's Investors Service
26 Jun 2023	Rating Action	Moody's confirms Catalent B1 CFR; outlook stable	Moody's Investors Service
13 Jun 2023	Credit Opinion	Catalent Pharma Solutions, Inc.: Update to credit analysis following downgrade to B1/RUR	Moody's Investors Service
07 Jun 2023	Rating Action	Moody's downgrades Catalent to B1; ratings remain under review for downgrade	Moody's Investors Service
18 Apr 2023	Credit Opinion	Catalent Pharma Solutions, Inc.: Update to credit analysis following review for downgrade	Moody's Investors Service
17 Apr 2023	Rating Action	Moody's places Catalent's ratings under review for downgrade following profit warning	Moody's Investors Service
10 Jan 2023	Credit Opinion	Catalent Pharma Solutions, Inc.: Recent investments will support earnings growth and deleveraging as COVID revenues dwindle rapidly	Moody's Investors Service
05 Jan 2023	Covenant Quality Assessment	Catalent Pharma Solutions, Inc.: Covenant Quality Post-Sale Snapshot: $650m 3.5% Senior Notes due 2030	Moody's Investors Service
28 Oct 2022	Covenant Quality Assessment	Catalent Pharma Solutions, Inc.: Covenant Quality Post-Sale Snapshot: $550m 3.125% Senior Notes due 2029	Moody's Investors Service
27 Oct 2022	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Healthcare Service issuers	Moody's Investors Service
15 Dec 2021	Credit Opinion	Catalent Pharma Solutions, Inc.: Update to credit analysis	Moody's Investors Service
14 Dec 2021	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc.	Moody's Investors Service
23 Sep 2021	Rating Action	Moody's assigns B1 rating to Catalent's notes offering	Moody's Investors Service
10 Feb 2021	Rating Action	Moody's assigns B1 rating to Catalent's notes offering	Moody's Investors Service
03 Feb 2021	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc.	Moody's Investors Service
04 Dec 2020	Credit Opinion	Catalent Pharma Solutions, Inc.: Update following upgrade of CFR to Ba3	Moody's Investors Service
24 Nov 2020	Credit Opinion	Catalent Pharma Solutions, Inc.: Update following upgrade of CFR to Ba3	Moody's Investors Service
18 Nov 2020	Rating Action	Moody's upgrades Catalent's CFR to Ba3; outlook stable	Moody's Investors Service
20 Mar 2020	Covenant Quality Assessment	Catalent Pharma Solutions, Inc.: Covenant Quality Post-Sale Snapshot: €825m 2.375% Senior Notes due 2028	Moody's Investors Service
06 Mar 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc.	Moody's Investors Service
05 Mar 2020	Credit Opinion	Catalent Pharma Solutions, Inc.: Update following upgrade of senior secured rating to Ba2	Moody's Investors Service
05 Mar 2020	LGD Assessment	Catalent Inc.	Moody's Investors Service
28 Feb 2020	Rating Action	Moody's upgrades Catalent's senior secured rating to Ba2, affirms B1 CFR; the outlook remains stable	Moody's Investors Service
19 Feb 2020	Rating Action	Moody's assigns B3 rating to Catalent's notes offering	Moody's Investors Service
04 Feb 2020	Issuer Comment	Catalent Pharma Solutions, Inc.: Equity funded acquisition of MaSTherCell is credit positive	Moody's Investors Service
25 Jul 2019	Covenant Quality Assessment	Catalent Pharma Solutions, Inc.: Loan Covenant Quality Snapshot	Moody's Investors Service
25 Jun 2019	Covenant Quality Assessment	Catalent Pharma Solutions, Inc.: Covenant Quality Pre-Sale Snapshot: $500m _% Senior Notes due 2027	Moody's Investors Service
24 Jun 2019	Rating Action	Moody's assigns B3 rating to Catalent's notes offering	Moody's Investors Service
13 May 2019	Credit Opinion	Catalent Pharma Solutions, Inc.: Update following downgrade of senior secured rating to Ba3	Moody's Investors Service
09 May 2019	Rating Action	Moody's downgrades Catalent's senior secured rating to Ba3, affirms B1 CFR rating; the outlook remains stable	Moody's Investors Service
17 Apr 2019	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc.	Moody's Investors Service
17 Apr 2019	Announcement	Moody's: Catalent's acquisition of Paragon will increase leverage, a credit negative	Moody's Investors Service
16 Apr 2019	Issuer Comment	Catalent Pharma Solutions, Inc.: Acquisition of Paragon will increase leverage, a credit negative	Moody's Investors Service
27 Nov 2018	Credit Opinion	Catalent Pharma Solutions, Inc.: Update to discussion of key credit factors	Moody's Investors Service
06 Aug 2018	Rating Action	Moody's upgrades Catalent's senior secured ratings to Ba2	Moody's Investors Service
24 Jul 2018	Announcement	Moody's: Catalent's plan to use equity offering proceeds for debt repayment is credit positive	Moody's Investors Service
24 Jul 2018	Issuer Comment	Catalent Pharma Solutions, Inc.: Intent to repay debt with equity offering proceeds is credit positive	Moody's Investors Service
13 Jul 2018	LGD Assessment	Catalent Pharma Solutions, Inc.	Moody's Investors Service
16 Nov 2017	Credit Opinion	Catalent Pharma Solutions, Inc.: Update to credit analysis	Moody's Investors Service
12 Oct 2017	Announcement	Moody's Publishes Covenant Quality Assessment for Catalent Pharma Solutions, Inc. Bond Offering	Moody's Investors Service
12 Oct 2017	Covenant Quality Assessment	Catalent Pharma Solutions, Inc.: Covenant Quality Pre-Sale Snapshot: $450m _% Senior Notes due 2026	Moody's Investors Service
10 Oct 2017	Rating Action	Moody's assigns B3 rating to Catalent's new senior unsecured notes	Moody's Investors Service
04 Oct 2017	Rating Action	Moody's assigns Ba3 ratings to Catalent's new senior secured credit facilities	Moody's Investors Service
25 Sep 2017	Issuer Comment	Catalent Pharma Solutions' Planned Acquisition of Cook Pharmica Is Credit Positive	Moody's Investors Service
20 Sep 2017	Rating Action	Moody's affirms Catalent's B1 CFR; outlook stable	Moody's Investors Service
01 Dec 2016	Covenant Quality Assessment	Catalent Pharma Solutions, Inc.: Covenant Quality Pre-Sale Snapshot: € ($400m equivalent) _% Senior Notes due 2024	Moody's Investors Service

Resultados 1 - 50 de 76

Página de 2 Next

Informes & Calificaciones

Productos & Soluciones

Noticias & Eventos

Usuarios Registrados

No se ha registrado?

Moody's Integrity Hotline

Via the Internet:

By telephone from the United States:

By telephone from outside the United States: